Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Open Access
- 10 January 2019
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 1-10
Abstract
High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse. Using publicly available data, we estimated the differences in trial characteristics and clinical development costs with 100 orphan and 100 non-orphan drugs. We found that the out-of-pocket clinical costs per approved orphan drug to be $166 million and $291 million (2013 USD) per non-orphan drug. The capitalized clinical costs per approved orphan drug and non-orphan drug were estimated to be $291 million and $412 million respectively. When focusing on new molecular entities only, we found that the capitalized clinical cost per approved orphan drug was half that of a non-orphan drug. More discussion is needed to better align on which cost components should be included in research and development costs for pharmaceuticals.Keywords
This publication has 14 references indexed in Scilit:
- The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug SpaceDrug Development Research, 2014
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Pricing for Orphan DrugsJAMA, 2013
- Orphan drug development: an economically viable strategy for biopharma R&DDrug Discovery Today, 2012
- Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010JAMA, 2012
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Rare diseases, orphan drugs and their regulation: questions and misconceptionsNature Reviews Drug Discovery, 2010
- Orphan drug: Development trends and strategiesJournal of Pharmacy and Bioallied Sciences, 2010
- Pivotal studies of orphan drugs approved for neurological diseasesAnnals of Neurology, 2009
- Does orphan drug legislation really answer the needs of patients?The Lancet, 2008